Form D · Biotechnology

ANSUN BIOPHARMA, INC.

San Diego, CA · CIK 0001534671

Offering snapshot reported Nov 24, 2020 · SEC filing

Reported sold
$100M
Offering amount: $100M
Investors reported
19
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
Jul 17, 2019
As reported in this filing

Fundraising history

Reported sold
Reported amount sold by Form D filing date$0$50M$100MSep 9, 2019: $78,375,000.00Sep 9, 2019Nov 24, 2020: $100,000,000.00Nov 24, 2020

Dates are filing dates, not cash receipt dates. Decreases are reported revisions, not evidence of withdrawals. Separate offering histories are not added together.

What changed?

Latest filing versus its linked predecessor, where available.

  • Reported sold$78,375,000 → $100,000,000
  • Reported investors12 → 19

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Nov 24, 2020Amendment$100,000,000$21,625,000vs Sep 9, 201919SEC filing
Sep 9, 2019Initial$78,375,000No comparison12SEC filing
Aug 29, 2019Initial$67,088,386No comparison29SEC filing
Mar 28, 2018Initial$1,650,000No comparison6SEC filing
Dec 22, 2015Initial$4,000,000No comparison6SEC filing
May 23, 2014Initial$7,500,000No comparison7SEC filing
May 29, 2013Initial$5,000,000No comparison9SEC filing
Nov 10, 2011Initial$9,900,000No comparison6SEC filing

Offering details

Securities
Equity
Exemptions
06b
Duration over one year
No
Business combination
No
Sales commissions
$960K
Finders' fees
$0
Form D file number
021-348287

Sales compensation recipients

Scroll to see all columns →

RecipientCRDAssociated broker-dealer
China Renaissance Securities (US) Inc.166318

Source: Form D, filed Nov 24, 2020. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Mark Attebury Executive
Michael Chang Director
Nancy Chang Director, Executive
Michael Chao Director
Allen Chao Director
Dave Chenn Director
Michael Havluciyan Executive
Mikael Havluciyan Executive
Karen Liu Director
Ron Moss Executive
Ronald Moss Executive
Donald Payne Director
Yi Shi Director
Aimin Wu Director
Shi Yi Director
Yining Zhao Executive

Issuer details

Industry: Biotechnology (See others in industry)

Address:
3030 Callan Road, Suite 200
San Diego, CA, 92121